Nirogy Therapeutics to Present at AACR Annual Meeting 2022

Two posters highlighting preclinical data of a small molecule development candidate with a novel mechanism of immune activation in the TME and cancer cell intrinsic killing demonstrate significant efficacy across broader tumor types: the potential treatment as a monotherapy or in combination with immune checkpoint inhibitors

Boston, April 5, 2022 – Nirogy Therapeutics Inc., a privately-held biotechnology company developing novel small molecules to target cellular transporters, today announced that the company will present two posters at the 2022 American Association for Cancer Research (AACR) Annual Meeting, to be held during April 8-13, 2022.

Nirogy will highlight preliminary data that shows NGY-B, the company’s first-in-class, orally bioavailable small molecule lactate transport inhibitor, intervenes in multiple pathways of metabolism while locally activates anti-tumor immunity in the tumor microenvironment (TME), providing a novel therapeutic modality to combat broader tumor types.

“We’re excited to present two impactful posters which highlight our multi-pronged approach to address significant unmet medical need for hard-to-treat tumors at this year’s AACR conference” said Vincent Sandanayaka, Ph.D., founder, president, and chief scientific officer of Nirogy. “These preliminary data show that NGY-B has significant efficacy in ‘immunologically cold’ syngeneic and patient-derived xenograft mouse models in triple negative breast cancer, ovarian and renal cell carcinoma where currently no effective therapies are available. We have also observed further enhancement of efficacy of this compound by combining with immune checkpoint blockade such as anti-PD-1 and anti-CTLA4 inhibitors, suggesting a potential future combination therapy to address resistance mechanisms developed by checkpoint inhibitors. We look forward to sharing additional data as we move the development candidate to the clinic in the coming months.”

Poster Presentation Details

Title: Efficacy of a Small Molecule Inhibitor of MCT1 and MCT4 Transporters in Cancer
Presenters: Sambad Sharma, Gregory J Goreczny, Nicole Bowman, Jennifer Duffy, Daliya Banergee, Kerui Wu, Abhishek Tyagi, Shih-Ying Wu, Kounosuke Watabe, John Dzuris, Jaime Escobedo, Vincent Sandanayaka
Session: Novel Targets and Pathways
Poster Section: 24
Presentation Number: 5719
Date and Time: Tuesday, April 12, 2022, 9:00 a.m. – 12:30 p.m. CST

Title: NGY-B is a Novel Inhibitor of MCT Transporters Blocking Lactate and Glucose Metabolisms
Presenters: Sambad Sharma, Gregory J Goreczny, Nicole Bowman, Jennifer Duffy, Daliya Banerjee, Sanath Wijerathna, John Dzuris, Jaime Escobedo, Vincent Sandanayaka
Session: New Chemotherapy Agents
Poster Section: 27
Presentation Number: 5632
Date and Time: Wednesday, April 13, 2022, 9:00 a.m. – 12:30 p.m. CST

About Nirogy

Nirogy Therapeutics is a biotechnology company based in Boston, MA, developing novel small molecules to target cellular transporters. The company is currently advancing a class of small molecules intended to disrupt metabolic and immune mechanisms operative in the tumor microenvironment. Follow-on platform programs are targeting additional disease pathways in oncology as well as autoimmune diseases.

For more information, please visit www.nirogytx.com or follow us on Twitter and LinkedIn.

More Posts

Share:

Send Us A Message

Scroll to Top

This website uses cookies to ensure you get the best experience on our website.

Vincent P. Sandanayaka, Ph.D.

FOUNDER

At vero eos et accusamus et iusto odio dignissimos ducimus qui blanditiis praesentium voluptatum deleniti atque corrupti quos dolores et quas molestias excepturi sint occaecati cupiditate non provident, similique sunt in culpa qui officia deserunt mollitia animi, id est laborum et dolorum fuga. Et harum quidem rerum facilis est et expedita distinctio. Nam libero tempore, cum soluta nobis est eligendi optio cumque nihil impedit quo minus id quod maxime placeat facere possimus, omnis voluptas assumenda est, omnis dolor repellendus. Temporibus autem quibusdam et aut officiis debitis aut rerum necessitatibus saepe eveniet ut et voluptates repudiandae sint et molestiae non recusandae. Itaque earum rerum hic tenetur a sapiente delectus, ut aut reiciendis voluptatibus maiores alias consequatur aut perferendis doloribus asperiores repellat